

1 Title Page

2

3 **Tumor necrosis factor- $\alpha$  gene polymorphism is associated with short- and long-term kidney**

4 **allograft outcomes**

5 Felix Poppelaars<sup>1</sup>, Mariana Gaya da Costa<sup>1,\*</sup>, Bernardo Faria<sup>1,2,\*</sup>, Siawosh K. Eskandari<sup>1</sup>, Marc A.

6 Seelen<sup>1</sup>, Jeffrey Damman<sup>3</sup>

7

8 \* Shared second author

9 <sup>1</sup> Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen,  
10 University of Groningen, Groningen, The Netherlands.

11 <sup>2</sup> Nephrology and Infectious Disease R&D Group, INEB, Institute of Investigation and Innovation in  
12 Health (i3S), University of Porto, Porto, Portugal.

13 <sup>3</sup> Department of Pathology, Erasmus Medical Center, University Medical Center, Rotterdam, The  
14 Netherlands.

15

16

17 Running head: genetic variant in *TNF* associates with graft loss.

18 Keywords: TNF- $\alpha$ , kidney transplantation, nephrology, genetics.

19

20

21 Word Title: 14 words

22 Running head: 50

23 Word count abstract 249 words

24 Word count body: 3.014 words

25 Number of pages: 29

26 Number of figures: 3

27 Number of tables: 4

28 References: 31

29

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Address for Correspondence:**

2 Felix Poppelaars, M.D./Ph.D.

3 University Medical Center Groningen

4 Department of internal medicine, Division of Nephrology, AA53

5 Postbus 196

6 9700 AD Groningen, The Netherlands

7 Phone: +31 50 3610544

8 Fax: +31 50 3619320

9 E-Mail: [f.poppelaars@umcg.nl](mailto:f.poppelaars@umcg.nl)

10

1 **Abbreviations**

2	DGF	Delayed graft function
3	HLA	Human leukocyte antigen
4	HR	Hazard ratio
5	OD	Odds ratio
6	PNF	Primary non-function
7	mAb	Monoclonal antibody
8	siRNA	Small interfering RNA
9	SNP	Single-nucleotide polymorphism
10	TNF- $\alpha$	Tumor necrosis factor alpha
11	<i>TNF</i>	Tumor necrosis factor alpha gene

1 **Abstract**

2

3 **Introduction**

4 Kidney transplantation has excellent short-term results with current immunosuppression regimes, but  
5 long-term outcomes have barely improved. Hence, there is a need for new therapeutic options to  
6 increase long-term survival of kidney grafts. Drug development for transplantation has slowly plateaued,  
7 limiting progress while making drug repurposing an attractive alternative. We, therefore, investigated  
8 the impact of tumor necrosis factor-alpha (TNF- $\alpha$ ) gene (*TNF*) polymorphisms on kidney graft survival.

9 **Methods**

10 We performed a prospective cohort study to assess the association of *TNF* polymorphisms (rs1800629  
11 G>A and rs3093662 A>G) with primary non-function (PNF) and death-censored kidney allograft survival  
12 in 1,271 kidney transplant pairs from the University Medical Center Groningen in The Netherlands.

13 **Results**

14 The G-allele of the *TNF* rs3093662 polymorphism in donor kidneys was associated with a higher risk of  
15 PNF (odds ratio: 2.05; 95%-CI: 1.06-3.97;  $P = 0.032$ ). Furthermore, the G-allele of this *TNF* rs3093662  
16 polymorphism in the donor was also associated with worse 5-year, 10-year, and 15-year death-censored  
17 kidney graft survival ( $P < 0.05$ ). The cumulative incidence of graft loss was 15.9% in the reference AA-  
18 genotype group and 25.2% in the AG/GG-genotype group, respectively. In multivariable analysis, the  
19 association between the *TNF* rs3093662 polymorphism in the donor and 15-year death-censored kidney  
20 graft survival remained significant (hazard ratio: 1.51; 95%-CI: 1.05-2.19,  $P = 0.028$ ).

21 **Conclusion**

22 Kidney allografts possessing a high-producing *TNF* polymorphism have a greater risk of immediate and  
23 late graft loss. Our study adds to a growing body of literature indicating the potential of TNF- $\alpha$  blockade  
24 in improving kidney transplantation outcomes.

25

## 1 Introduction

2 Kidney transplantation has excellent short-term outcomes with current immunosuppression regimes,  
3 while long-term allograft survival has barely improved over the past decades.<sup>1</sup> Consequently, there is a  
4 need for new therapies that can increase the long-term survival of kidney grafts in transplant recipients.  
5 Drug development in nephrology and transplantation has been slow and limited in the past twenty years  
6 for a multitude of reasons, most notable of which are the steep costs of developing new drugs and  
7 identifying and enrolling the patients for clinical trials.<sup>2,3</sup> Multi-disciplinary efforts are now underway to  
8 accelerate the process of drug development for renal transplant patients.<sup>3,4</sup> Simultaneously, drug  
9 repurposing is seen as an attractive alternative to the traditional drug discovery process.<sup>5</sup> With drug  
10 repurposing investigators explore new indications of use for investigational or previously approved drugs.  
11 Notably, this approach is low-cost, time-saving, risk-averse, and, therefore, highly efficient.<sup>5</sup> Recycling  
12 existing anti-inflammatory drugs for kidney transplantation, thus, should be considered to improve long-  
13 term transplant outcomes.

14 Cytokines induce and enhance the immune response to combat invading microorganisms, but  
15 can also cause severe host injury or disease if the activation of this inflammatory response is excessive  
16 or unwanted.<sup>6</sup> Among all cytokines, tumor necrosis factor-alpha (TNF- $\alpha$ ) continues to be one of the most  
17 extensively studied.<sup>7</sup> Currently, there are five therapeutic agents in clinical use that target TNF- $\alpha$ ; Four  
18 monoclonal antibodies (mAb; Infliximab, Centolizumab, Adalimumab, and Golimumab) and one fusion  
19 protein (Etanercept).<sup>8</sup> The clinical success of TNF- $\alpha$  targeted therapies in rheumatologic disorders and  
20 inflammatory bowel diseases has helped to establish these biologicals as the mainstay treatment for  
21 autoimmune diseases.<sup>9,10</sup> Currently, there is substantial evidence that TNF- $\alpha$  plays an equally important  
22 role in renal inflammation and fibrosis.<sup>11</sup> Several studies have also demonstrated the importance of TNF-  
23  $\alpha$  in renal ischemia-reperfusion injury by using a variety of TNF- $\alpha$  blocking strategies.<sup>12-14</sup> On this basis,  
24 TNF- $\alpha$  inhibitors have therefore been proposed for use in kidney transplant recipients to improve  
25 outcome.<sup>15</sup>

26 Here, we used human genetics to probe whether targeting TNF- $\alpha$  in renal transplantation will  
27 provide clinical benefit. Studies of human genetics are powerful tools in validating therapeutic targets  
28 because genetically-backed drug targets are reported to be twice as likely to lead to approved  
29 therapeutics compared to traditional drug discovery targets.<sup>16,17</sup> Hence, we investigated the association

- 1 between two common functional TNF- $\alpha$  gene (*TNF*) polymorphisms and kidney graft survival in donor-
- 2 recipient renal transplant pairs.
- 3

## 1 **Methods**

2

### 3 **Patient selection and study end-point**

4 Patients were enrolled if they underwent single kidney transplantation between March 1993 and  
5 February 2008 at the University Medical Center Groningen (UMCG) in the Netherlands. A total of 1,430  
6 kidney transplantations were screened for analysis. Of these, 1,271 donor and recipient kidney  
7 transplant pairs were included in the study as previously described.<sup>18–20</sup> Exclusion criteria included lack  
8 of DNA, technical complications during surgery, loss of follow-up or re-transplantation. The current work  
9 is in line with the declaration of Helsinki and all subjects provided written informed consent. Additionally,  
10 the study was approved by the medical ethics committee of the UMCG under file n° METc 2014/077.  
11 The primary endpoint of our study was primary non-function (PNF) and long-term death-censored graft  
12 survival, defined as the need for re-transplantation or dialysis.

13

### 14 **DNA extraction and *TNF* genotyping**

15 Blood was obtained for the isolation of peripheral blood mononuclear cells or splenocytes were collected  
16 from the donors and recipients. Isolation of DNA was performed with a commercial kit according to the  
17 manufacturer's instructions and stored at -80°C. Genotyping of single nucleotide polymorphisms (SNPs)  
18 was determined using the Illumina VeraCode GoldenGate Assay kit as per the manufacturer's  
19 instructions (Illumina, San Diego, CA, USA). Genotype clustering and calling were performed using  
20 BeadStudio Software (Illumina). The overall genotype success rate was 99.5% and 6 samples with a  
21 high missing call rate were excluded from subsequent analyses.

22

### 23 **Statistical analysis**

24 SPSS software version 25 (SPSS Inc, Chicago, IL, USA) was used to perform statistical analyses. Data  
25 are presented as median [IQR] for non-parametric variables, mean  $\pm$  standard deviation for parametric  
26 variables, and nominal variables as the total number of patients with percentage [n (%)]. Groups were  
27 assessed for differences with the Mann-Whitney U test for not-normally divided variables or Student t-  
28 test for normally distributed variables, and  $\chi^2$  test for categorical variables, respectively. The Log-rank  
29 test was used to determine the difference in the graft loss frequency between different genotypes.  
30 Univariable analysis was used to assess the association of genetic, recipient, donor, and transplant

1 characteristics with graft loss. The variables identified in these analyses were next examined in a  
2 multivariable Cox regression with a stepwise forward selection. Statistical testing was 2-tailed and  $P < 0.05$   
3 was regarded as significant.

4



## 1 Results

2

### 3 Population characteristics

4 The characteristics of all donor and recipient kidney transplant pairs are shown in **Table 1**. The maximum  
5 study period was 15 years, with a mean follow-up after transplantation of 6.16 years  $\pm$  4.21. During the  
6 study period, 214 grafts (17.4%) were lost with the main causes of graft loss being rejection ( $n = 126$ ),  
7 surgical complications ( $n = 33$ ), recurrence of primary disease ( $n = 16$ ), vascular causes ( $n = 12$ ), other  
8 causes ( $n = 16$ ) and unknown ( $n = 11$ ). By univariable analysis, recipient age, donor age, donor type  
9 (living vs cadaveric), recipient blood type (AB vs others), donor blood type (AB vs others), cold ischemia  
10 time, warm ischemia time, use of corticosteroids, use of cyclosporin, and delayed graft function (DGF)  
11 were found to be associated with graft loss ( $P < 0.05$ ).

12 We genotyped two common polymorphisms of the *TNF*- $\alpha$  gene: rs1800629 G>A in the promoter  
13 region at position ~308 and rs3093662 A>G in the first intron at position ~851 (**Figure 1**). The observed  
14 genotypic frequencies of the *TNF* SNP rs1800629 G>A were significantly different between recipients  
15 ( $n = 1266$ ; GG, 58.3%; GA, 34.3%; AA, 7.0%) and donors ( $n = 1269$ ; GG, 68.1%; GA, 29.0%; AA, 2.7%)  
16 ( $P < 0.001$ ). More specifically, the A-allele of the *TNF* rs1800629 SNP was more prevalent in kidney  
17 transplant recipients. The frequency of the *TNF* rs1800629-A variant were also significantly higher in  
18 both donors and recipients than those reported by the 1000 genomes project ( $P < 0.001$ ).<sup>21</sup> The observed  
19 genotypic frequencies of the *TNF* rs3093662 A>G was not significantly different between recipients ( $n$   
20 = 1270; AA, 89.3%; GA, 10.6%) and donors ( $n = 1267$ ; AA, 88.4%; AG, 10.9%; GG, 0.4%) ( $P = 0.08$ ).  
21 Yet, the frequency of the *TNF* rs3093662-G variant described in the 1000 genomes project was  
22 significantly higher than those in the donors ( $P = 0.003$ ) and recipients ( $P < 0.001$ ).<sup>21</sup> Due to the low  
23 frequency in donors of the *TNF* rs3093662 polymorphism GG-genotype, heterozygotes (AG) and  
24 homozygotes (GG)-genotypes were combined to one group (AG/GG). Lastly, the distribution of both  
25 polymorphisms was in Hardy–Weinberg equilibrium.

26

### 27 A genetic variant in *TNF* is a risk factor for early graft loss after kidney transplantation

28 We first studied whether genetic variants in *TNF* are associated with PNF to assess the impact on early  
29 graft loss. For the *TNF* rs3093662 A>G polymorphism, the proportion of grafts with PNF significantly  
30 differed based on the donor genotype (4.3% PNF in the AA-genotype group vs. 8.4% PNF in the AG/GG-

1 group,  $P = 0.029$ ), but not for recipient genotype ( $P = 0.31$ ) (Table 2). In univariable logistic regression,  
2 donors carrying the G-allele of the *TNF* rs3093662 A>G polymorphism had a significantly higher risk of  
3 PNF (OR = 2.05 compared to A-allele; 95%-CI: 1.06 – 3.97;  $P = 0.032$ ). Next, we performed a  
4 multivariable logistic regression analysis with a stepwise forward selection procedure using all  
5 characteristics that were significantly associated with PNF in univariable logistic regression (Table 3).  
6 In the final model, the *TNF* rs3093662 A>G polymorphism in the donor, donor age, donor type (living vs  
7 cadaveric), recipient sex, recipient blood type (AB vs others), and warm ischemia time were included.  
8 After adjustment, the G-allele of rs3093662 in the donor was significantly associated with graft loss with  
9 an odds ratio of 2.16 (95% CI: 1.07 – 4.37,  $P = 0.032$ ). For the other *TNF* polymorphism, namely  
10 rs1800629 G>A, the proportion of grafts with PNF did not significantly differ based on the recipient  
11 genotype ( $P = 0.40$ ), or donor genotype ( $P = 0.35$ ). In conclusion, our data show that the minor allele of  
12 the *TNF* rs3093662 A>G SNP in the donor associates with a higher risk of immediate graft loss after  
13 kidney transplantation.

14

#### 15 **A genetic variant in *TNF* is a risk factor for late graft loss after kidney transplantation**

16 Next, we studied whether the genetic variants in *TNF* are associated with kidney allograft survival to  
17 evaluate the relationship between these polymorphisms and late graft loss. No association was found  
18 between 15-year death-censored kidney graft survival and the *TNF* rs1800629 G>A polymorphism in  
19 the donor (Supplementary data,  $P = 0.64$ ) or the recipient (Supplementary data,  $P = 0.66$ ). Conversely,  
20 Kaplan–Meier survival analysis once again revealed that the G-allele of the *TNF* rs3093662  
21 polymorphism in the donor was significantly associated with worse 5-year, 10-year, and 15-year death-  
22 censored kidney graft survival (Fig. 2A–C). After 15 years of follow-up, the cumulative incidence of graft  
23 loss was 15.9% in the reference AA-genotype group and 25.2% in the AG/GG-genotype group,  
24 respectively. The association of the G-allele with late graft loss was maintained when PNF cases were  
25 excluded (Fig. 2D,  $P = 0.047$ ), thereby demonstrating that the association between the *TNF* rs3093662  
26 polymorphism and long-term graft survival is independent of its association with early graft loss. We  
27 next performed a subgroup analysis for the donor type, since deceased organ donors have elevated  
28 levels of circulating pro-inflammatory cytokines. Kaplan-Meier curves demonstrated that the association  
29 remained significant between the *TNF* rs3093662 polymorphism and long-term graft survival in kidney  
30 allografts from living donors (Fig. 3A,  $P = 0.027$ ) as well as from deceased donors (Fig. 3B,  $P = 0.023$ ).

1 The *TNF* rs3093662 polymorphism in the recipient was not associated with graft survival rates  
2 (Supplementary data,  $P = 0.52$ ).

3 We additionally examined whether the G-allele of the *TNF* rs3093662 polymorphism in the donor  
4 was independently associated with long-term graft survival. In univariable analysis, the G-allele of the  
5 *TNF* rs3093662 polymorphism in the donor was associated with a hazard ratio of 1.67 (95%-CI: 1.16 –  
6 2.38;  $P = 0.005$ ) for graft loss after 15 years of follow-up. Subsequently, we performed a multivariable  
7 analysis to adjust for potential confounders using a stepwise forward selection procedure with all clinical  
8 variables that were significantly associated with kidney graft survival in univariable analysis (Table 4).  
9 In the final model, the *TNF* rs3093662 SNP in the donor, recipient and donor age, recipient blood type  
10 (AB vs others), and DGF were included. After adjustment, the G-allele of the *TNF* rs3093662  
11 polymorphism in the donor remained significantly associated with graft loss after 15-years with a hazard  
12 ratio of 1.51 (95% CI: 1.05 – 2.19,  $P = 0.028$ ). In conclusion, our results demonstrate that the minor allele  
13 of the *TNF* rs3093662 (A>G) variant in the donor associates with a higher risk of late graft loss after  
14 kidney transplantation.

15

## 1 Discussion

2 The primary finding of our study is that a donor genetic variant in *TNF* associates with an increased risk  
3 for graft loss after kidney transplantation. This *TNF* polymorphism in the donor was independently  
4 associated with both a higher risk for immediate as well as late graft loss. Extending these findings, the  
5 relationship between the *TNF* rs3093662 polymorphism and long-term kidney allograft survival  
6 remained significant in a subgroup analysis for different types of kidney transplants. In contrast, long-  
7 term graft survival was not impacted by the *TNF* rs3093662 polymorphism in the recipient, nor by the  
8 *TNF* rs1800629 polymorphism. In conclusion, our data provide genetic evidence that targeting TNF- $\alpha$   
9 in renal transplantation could be favorable for long-term graft survival in kidney transplantation and  
10 encourages the study of TNF- $\alpha$  inhibitors in kidney transplantation in randomized controlled trials.

11 To our knowledge, our study is the first to show that the *TNF* rs3093662 polymorphism in the  
12 donor impacts the risk of both early and late graft loss after kidney transplantation. To summarize, we  
13 demonstrated that the G-allele in the donor nearly doubled the risk of immediate graft loss, while the  
14 relative risk of late graft loss increased by 58%. *In vivo* evidence regarding the functional consequences  
15 of the *TNF* rs3093662 polymorphism was recently presented, establishing the association of the G-allele  
16 with higher serum levels of TNF- $\alpha$  in both healthy and diseased individuals.<sup>22</sup> Previously, Israni *et al.*  
17 also found an association between the *TNF* polymorphism rs3093662 G-allele in the donor and DGF  
18 after kidney transplantation.<sup>23</sup> Although we could not confirm this association (data not shown), the  
19 results of Israni and colleagues are in line with our findings that this high-producing variant is detrimental  
20 in kidney allografts. Furthermore, in accordance with our study, the G-allele of the *TNF* rs3093662  
21 polymorphism has previously been associated with increased risks of rheumatoid arthritis, adverse  
22 events in cancer patients as well as with the susceptibility to and severity of pneumonia.<sup>22,24,25</sup> Altogether,  
23 these studies suggest a pro-inflammatory effect of this high-producing *TNF* polymorphism, thereby  
24 increasing the risk for a wide spectrum of immune-mediated diseases.

25 The clinical use of TNF- $\alpha$  targeted therapeutics has revolutionized the management of  
26 inflammatory disorders and autoimmune diseases. In preclinical transplantation studies, TNF- $\alpha$   
27 blockade showed significant protection against renal ischemia-reperfusion injury.<sup>12-14</sup> The underlying  
28 protective mechanisms behind targeting TNF- $\alpha$  include: (i) Modulating immune cell functions, (ii)  
29 Inhibiting inflammatory mediators, (iii) Protecting kidney cells from apoptosis, and (iv) Stimulating tissue  
30 regeneration.<sup>7,10</sup> Application of TNF- $\alpha$  antagonists in kidney transplantation would be especially

1 interesting given the extensive clinical experience with this biological. Recently, a meta-analysis found  
2 no significant increase in the infection rate among transplantation patients already on TNF- $\alpha$  inhibitors  
3 due to inflammatory bowel disease.<sup>26</sup> However, an observational study, comparing seven renal  
4 transplant recipients who resumed their TNF- $\alpha$  inhibitors after transplantation to seven recipients who  
5 did not, found that malignancies occurred more frequently.<sup>27</sup> Etanercept, a fusion protein TNF- $\alpha$  inhibitor,  
6 has already been tested in kidney transplantation during hypothermic machine perfusion. However, no  
7 differences were seen in renal transplant outcomes between the groups.<sup>28</sup> Finally, a Phase 2, double-  
8 blind, multicenter, randomized controlled trial of 300 deceased donor kidney transplant recipients has  
9 just been completed (NCT02495077). In this trial, a mAb targeting TNF- $\alpha$  (Infliximab) was given to  
10 recipients prior to transplantation, in addition to current immunosuppressive regimens, with kidney  
11 function at 2 years post-transplantation as the primary outcome. The results of this trial are anxiously  
12 awaited by the transplant community and will help define the clinical role of TNF- $\alpha$  inhibitors in kidney  
13 transplantation.

14 The present study found that a *TNF* genetic variant (rs3093662 A>G) in the donor, but not in  
15 the recipient, associated with the risk of graft loss after kidney transplantation. Our findings indicate that  
16 it is not circulating TNF- $\alpha$  from the recipient, but rather the release of TNF- $\alpha$  by the allograft that  
17 contributes to kidney transplant failure. These results provide important considerations for anti-TNF- $\alpha$   
18 therapies in kidney transplantation. TNF- $\alpha$  inhibitors that are currently used in clinical practice are either  
19 antibodies or soluble TNF- $\alpha$  receptors with distinct pharmacodynamic profiles and side-effects related  
20 to systemic exposure. However, if the donor kidney is the site of action, small interfering RNA (siRNA)  
21 or antisense oligonucleotides could be a more favorable approach due to better drug penetration into  
22 the donor kidney.<sup>29</sup> The association we found between donor genetics and transplant outcomes  
23 suggests that donor pre-treatment with TNF- $\alpha$  inhibitors should also be considered. Interventions within  
24 the donor may protect against a proinflammatory reaction after transplantation, and therefore, donor  
25 pre-treatment could be a promising strategy to increase graft function and survival.<sup>30,31</sup> Conversely,  
26 donor pre-treatment is not possible until it is known whether other donor organs (i.e., the liver, heart,  
27 and lungs) also benefit from targeting TNF- $\alpha$ .

28 The current study has several limitations that warrant consideration. First, a causality of the  
29 observed association cannot be established by this observational study as further work must be done  
30 to confirm our results. Second, we only investigated the association of two *TNF* polymorphisms with

1 outcome and did not look at *TNF* haplotypes. Third, because of the lack of plasma samples, we could  
2 not examine the differences in TNF- $\alpha$  plasma levels between the *TNF* genotypes. However, important  
3 strengths of our study include the prospective design, the large sample size, the long follow-up time,  
4 and the clinically meaningful endpoint (i.e., graft loss).

5 In conclusion, we found that kidney allografts possessing a *TNF* polymorphism, that has been  
6 associated with higher TNF- $\alpha$  levels, have a greater risk of immediate and late graft loss after kidney  
7 transplantation. Our study adds to the growing body of literature showing that TNF- $\alpha$  blockade in kidney  
8 transplantation has the potential to improve transplant outcomes. Following up on this work with clinical  
9 trials using TNF- $\alpha$  inhibitors is necessary to determine the ideal setting, including the timing of  
10 intervention, in which these biologicals might be effective.

1    **Disclosure**

2    The authors of this paper declare that they have no competing interests.

3

4    **Acknowledgment**

5    The authors thank the members of the REGaTTA cohort (REnal GeneTics TrAnsplantation; University

6    Medical Center Groningen, University of Groningen, Groningen, the Netherlands): S. J. L. Bakker, J.

7    van den Born, M. H. de Borst, H. van Goor, J. L. Hillebrands, B. G. Hepkema, G. J. Navis and H. Snieder.

8    The illustrations of Figure 1 were made by Siawosh K. Eskandari.

9

## 1   **References**

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

1.    Wekerle T, Segev D, Lechler R, Oberbauer R. Strategies for long-term preservation of kidney graft function. *Lancet*. 2017;389(10084):2152-2162. doi:10.1016/S0140-6736(17)31283-7
2.    Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. *Nat Rev Drug Discov*. 2016;15(8):568-588. doi:10.1038/nrd.2016.67
3.    Stegall MD, Troy Somerville K, Everly MJ, et al. The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. *Am J Transplant*. 2019;19(3):625-632. doi:10.1111/ajt.15214
4.    Edmonston DL, Roe MT, Block G, et al. Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. *Am J Kidney Dis*. 2020;76(6):842-850. doi:10.1053/J.AJKD.2020.05.026
5.    Rudrapal M, J. Khairnar S, G. Jadhav A. Drug Repurposing (DR): An Emerging Approach in Drug Discovery. In: *Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications*. IntechOpen; 2020. doi:10.5772/intechopen.93193
6.    Holdsworth SR, Can PY. Cytokines: Names and numbers you should care about. *Clin J Am Soc Nephrol*. 2015;10(12):2243-2254. doi:10.2215/CJN.07590714
7.    Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: Live or let die. *Nat Rev Immunol*. 2015;15(6):362-374. doi:10.1038/nri3834
8.    Lim H, Lee SH, Lee HT, et al. Structural biology of the TNF $\alpha$  antagonists used in the treatment of rheumatoid arthritis. *Int J Mol Sci*. 2018;19(3). doi:10.3390/ijms19030768
9.    Jang D, Lee A-H, Shin H-Y, et al. The Role of Tumor Necrosis Factor Alpha (TNF- $\alpha$ ) in Autoimmune Disease and Current TNF- $\alpha$  Inhibitors in Therapeutics. *Int J Mol Sci*. 2021;22(5):1-16. doi:10.3390/IJMS22052719
10.   Kallioli GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. *Nat Rev Rheumatol*. 2016;12(1):49-62. doi:10.1038/nrrheum.2015.169
11.   Feldmann M, Pusey CD. Is there a role for TNF- $\alpha$  in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. *J Am Soc Nephrol*. 2006;17(5):1243-1252. doi:10.1681/ASN.2005121359



- 1 12. Nagata Y, Fujimoto M, Nakamura K, et al. Anti-TNF- $\alpha$  agent infliximab and splenectomy are  
2 protective against renal ischemia-reperfusion injury. *Transplantation*. 2016;100(8):1675-1682.  
3 doi:10.1097/TP.0000000000001222
- 4 13. Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E. The renal injury  
5 and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF-  
6  $\alpha$ R1: A comparison with infliximab treatment. *Eur J Pharmacol*. 2013;700(1-3):134-146.  
7 doi:10.1016/j.ejphar.2012.11.066
- 8 14. Tasdemir C, Tasdemir S, Vardi N, et al. Protective effect of infliximab on ischemia/reperfusion-  
9 induced damage in rat kidney. *Ren Fail*. 2012;34(9):1144-1149.  
10 doi:10.3109/0886022X.2012.717490
- 11 15. Moers C, Pol RA, De Borst MH. Tumor necrosis factor a blockade to ameliorate renal ischemia  
12 reperfusion injury: Potential implications for kidney transplantation. *Transplantation*.  
13 2016;100(8):1601-1602. doi:10.1097/TP.0000000000001221
- 14 16. King EA, Wade Davis J, Degner JF. Are drug targets with genetic support twice as likely to be  
15 approved? Revised estimates of the impact of genetic support for drug mechanisms on the  
16 probability of drug approval. *PLoS Genet*. 2019;15(12):e1008489.  
17 doi:10.1371/journal.pgen.1008489
- 18 17. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved  
19 drug indications. *Nat Genet*. 2015;47(8):856-860. doi:10.1038/ng.3314
- 20 18. Dessing MC, Kers J, Damman J, Navis GJ, Florquin S, Leemans JC. Donor and recipient  
21 genetic variants in NLRP3 associate with early acute rejection following kidney transplantation.  
22 *Sci Rep*. 2016;6. doi:10.1038/srep36315
- 23 19. Damman J, Daha MR, Leuvenink HG, et al. Association of complement C3 gene variants with  
24 renal transplant outcome of deceased cardiac dead donor kidneys. *Am J Transplant*.  
25 2012;12(3):660-668. doi:10.1111/j.1600-6143.2011.03880.x
- 26 20. Damman J, Kok JL, Snieder H, et al. Lectin complement pathway gene profile of the donor and  
27 recipient does not influence graft outcome after kidney transplantation. *Mol Immunol*.  
28 2012;50(1-2):1-8. doi:10.1016/j.molimm.2011.11.009
- 29 21. Auton A, Abecasis GR, Altshuler DM, et al. A global reference for human genetic variation.  
30 *Nature*. 2015;526(7571):68-74. doi:10.1038/nature15393

- 1 22. Zhang S, Zhan L, Zhu Y, Sun H, Xu X. Tumor Necrosis Factor Alpha Gene Polymorphisms  
2 Increase Susceptibility to Adenovirus Infection in Children and Are Correlated with Severity of  
3 Adenovirus-Associated Pneumonia. *Genet Test Mol Biomarkers*. 2020;24(12):761-770.  
4 doi:10.1089/gtmb.2020.0122
- 5 23. Israni AK, Li N, Cizman BB, et al. Association of Donor Inflammation- and Apoptosis-Related  
6 Genotypes and Delayed Allograft Function After Kidney Transplantation. *Am J Kidney Dis*.  
7 2008;52(2):331-339. doi:10.1053/j.ajkd.2008.05.006
- 8 24. Tang R, Sinnwell JP, Li J, Rider DN, de Andrade M, Biernacka JM. Identification of genes and  
9 haplotypes that predict rheumatoid arthritis using random forests. *BMC Proc*. 2009;3(Suppl  
10 7):S68. doi:10.1186/1753-6561-3-s7-s68
- 11 25. Köhl T, Behrens S, Jung AY, et al. Validation of inflammatory genetic variants associated with  
12 long-term cancer related fatigue in a large breast cancer cohort. *Brain Behav Immun*.  
13 2018;73:252-260. doi:10.1016/j.bbi.2018.05.009
- 14 26. van Meeteren MJW, Hayee B, Inderson A, et al. Safety of anti-TNF treatment in liver transplant  
15 recipients: A systematic review and metaanalysis. *J Crohn's Colitis*. 2017;11(9):1146-1151.  
16 doi:10.1093/ecco-jcc/jjx057
- 17 27. Quinn CS, Jorgenson MR, Descourouez JL, Muth BL, Astor BC, Mandelbrot DA. Management  
18 of Tumor Necrosis Factor  $\alpha$  Inhibitor Therapy After Renal Transplantation: A Comparative  
19 Analysis and Associated Outcomes. *Ann Pharmacother*. 2019;53(3):268-275.  
20 doi:10.1177/1060028018802814
- 21 28. Diuwe P, Domagala P, Durlík M, Trzebicki J, Chmura A, Kwiatkowski A. The effect of the use of  
22 a TNF-alpha inhibitor in hypothermic machine perfusion on kidney function after  
23 transplantation. *Contemp Clin Trials*. 2017;59:44-50. doi:10.1016/j.cct.2017.05.013
- 24 29. Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local tumor necrosis  
25 factor- $\alpha$  inhibition in inflammatory bowel disease. *Pharmaceutics*. 2020;12(6):1-31.  
26 doi:10.3390/pharmaceutics12060539
- 27 30. de Vries DK, Wijermars LGM, Reinders MEJ, Lindeman JHN, Schaapherder AFM. Donor pre-  
28 treatment in clinical kidney transplantation: A critical appraisal. *Clin Transplant*.  
29 2013;27(6):799-808. doi:10.1111/ctr.12261
- 30 31. O'Neill S, Oniscu GC. Donor pretreatment and machine perfusion: Current views. *Curr Opin*

1            *Organ Transplant.* 2020;25(1):59-65. doi:10.1097/MOT.0000000000000725

2

1            **Tables**

2

**1 Table 1: Baseline characteristics of the donors and recipients**

		All Patients (n = 1271)	Functioning graft (n = 1056)	Graft loss (n = 215)	P-value*	HR	P-value#
<b>Recipient</b>							
<b>TNF rs3093662 SNP</b>	AA, n (%)	1135 (89.4)	940 (89.1)	195 (90.7)	0.49		0.52
	AG, n (%)	135 (10.6)	115 (10.9)	20 (9.3)			
<b>TNF rs1800629 SNP</b>	GG, n (%)	741 (58.5)	619 (58.8)	122 (57.3)	0.69		0.80
	GA, n (%)	436 (34.4)	358 (34.0)	78 (36.6)			
	AA, n (%)	89 (7.0)	76 (7.2)	13 (6.1)			
Female sex, n (%)		532 (41.9)	449 (42.5)	83 (38.6)	0.29		0.21
Age, years		47.9 ± 13.5	48.5 ± 13.4	45.0 ± 13.2	<b>&lt;0.001</b>	0.99	<b>0.027</b>
Dialysis vintage, weeks		172 [91 – 263]	174 [87 – 261]	168 [109 – 270]	0.15		0.10
<b>Blood group Donor</b>							
Type O, n (%)		567 (44.6)	474 (44.9)	93 (43.3)	<b>0.004</b>	0.46	<b>0.002</b>
Type A, n (%)		536 (42.2)	448 (42.4)	88 (40.9)		0.46	<b>0.002</b>
Type B, n (%)		113 (8.9)	98 (9.3)	15 (7.0)		0.35	<b>0.002</b>
Type AB, n (%)		55 (4.3)	36 (3.4)	19 (8.8)		Ref	<b>0.008</b>
<b>Primary kidney disease</b>							
Glomerulonephritis, n (%)		340 (26.8)	271 (25.7)	69 (32.1)	0.32		0.45
Polycystic disease, n (%)		208 (16.4)	187 (17.7)	21 (9.8)			
Vascular disease, n (%)		145 (11.4)	122 (11.6)	23 (10.7)			
Pyelonephritis, n (%)		148 (11.6)	120 (11.4)	28 (13.0)			
Diabetes, n (%)		51 (4.0)	44 (4.2)	7 (3.3)			
Chronic, n (%)		168 (13.2)	134 (12.7)	34 (15.9)			
Other, n (%)		211 (16.6)	178 (16.9)	33 (15.3)			
<b>Immunosuppression</b>							
Anti-CD3 Moab, n (%)		19 (1.5)	14 (1.3)	5 (2.3)	0.27		0.51
ATG, n (%)		103 (8.1)	79 (7.5)	24 (11.2)	0.07		0.14
Azathioprine, n (%)		72 (5.7)	53 (5.0)	19 (8.8)	<b>0.027</b>		0.29
Corticosteroids, n (%)		1201 (94.5)	1002 (94.9)	199 (92.6)	0.17	0.51	<b>0.01</b>
Cyclosporin, n (%)		1085 (85.4)	911 (86.3)	174 (80.9)	<b>0.044</b>	0.66	<b>0.016</b>
Interleukin-2 RA, n (%)		199 (15.7)	163 (15.4)	36 (16.7)	0.63		0.12
Mycophenolic acid, n (%)		907 (71.4)	775 (73.4)	132 (61.4)	<b>&lt;0.001</b>		0.06
Sirolimus, n (%)		38 (3.0)	33 (3.1)	5 (2.3)	0.53		0.54
Tacrolimus, n (%)		97 (7.6)	77 (7.3)	20 (9.3)	0.31		0.39
<b>Donor</b>							
<b>TNF rs3093662 SNP</b>	AA, n (%)	1124 (88.7)	945 (89.8)	179 (83.3)	<b>0.006</b>	Ref	<b>0.005</b>
	AG/GG, n (%)	143 (11.3)	107 (10.2)	36 (16.7)		1.67	
<b>TNF rs1800629 SNP</b>	GG, n (%)	866 (68.2)	714 (67.7)	152 (70.7)	0.66		0.57
	GA, n (%)	369 (29.1)	312 (29.6)	57 (26.5)			
	AA, n (%)	34 (2.7)	28 (2.7)	6 (2.8)			
Female sex, n (%)		626 (49.3)	521 (49.3)	105 (48.8)	0.89		0.96
Age, years		44.4 ± 14.4	44.1 ± 14.6	46.1 ± 13.4	<b>0.044</b>	1.02	<b>&lt;0.001</b>
<b>Donor type</b>							
Living, n (%)		282 (22.2)	257 (24.3)	25 (11.6)	<b>&lt;0.001</b>	Ref	<b>0.002</b>
Brain death, n (%)		787 (61.9)	642 (60.8)	145 (67.4)		1.94	
Circulatory death, n (%)		202 (15.9)	157 (14.9)	45 (20.9)			
<b>Blood group</b>							
Type O, n (%)		642 (50.6)	541 (51.3)	101 (47.2)	<b>0.033</b>	0.39	<b>0.004</b>
Type A, n (%)		502 (39.6)	414 (39.3)	88 (41.1)		0.42	<b>0.01</b>
Type B, n (%)		97 (7.6)	82 (7.8)	15 (7.0)		0.36	<b>0.012</b>
Type AB, n (%)		27 (2.1)	17 (1.6)	10 (4.7)		Ref	<b>0.035</b>
<b>Transplantation</b>							
Highest PRA, in %		10.1 ± 23.6	9.98 ± 23.7	10.9 ± 25.0	0.54		0.75
Total HLA mismatches		2 [1 – 3]	2 [1 – 3]	2 [1 – 3]	0.48		0.11
CIT, in hours		17.7 [10.9 – 23.0]	17.0 [8.6 – 23.0]	20.0 [15.3 – 25.0]	<b>&lt;0.001</b>	1.03	<b>0.001</b>
WIT, in minutes		37.0 [31 – 45]	37.0 [30 – 45]	38.0 [32 – 45]	0.12	1.02	<b>0.003</b>
DGF, n (%)		415 (32.7)	289 (27.4)	126 (58.6)	<b>&lt;0.001</b>	3.79	<b>&lt;0.001</b>

1 The characteristics of all donor and recipient kidney transplant pairs as well as subgroup analysis for  
2 graft loss after 15 years of follow-up. Data are displayed as the total number of patients with percentage  
3 for nominal data [n (%)]; median [IQR] for non-parametric variables, and; mean  $\pm$  standard deviation for  
4 parametric variables.

5 Abbreviations: *ATG*, Anti-thymocyte globulin; *CD3*, cluster of differentiation *CIT*, cold ischemia time;  
6 *DGF*, delayed graft function; *HLA*, human leukocyte antigen; *PRA*, panel-reactive antibody; *3RA*,  
7 receptor antagonist; *SNP*, single nucleotide polymorphism; *TNF*, Tumor necrosis factor-alpha gene; *WIT*,  
8 warm ischemia time. Bold *P-values* indicate *P-values* that are statistically significant (*P-value* < 0.05).

9 *P-value*\* shows the P-value for the differences in baseline demographics among the groups, tested  
10 by  $\chi^2$  test for categorical variables, and Mann–Whitney U test or Student's t-Test for continuous  
11 variables.

12 *P-value*# shows the P-value for univariable analysis for 15-year death censored graft survival.  
13

1 **Table 2**

2 **Genotype frequency and hazard ratios for primary non-function based on TNF genotypes**

<i>TNF</i> <i>rs3093662</i> <i>SNP</i>	Primary non-function		Immediate graft function		<i>P</i> -value	Odds ratio (95%-CI)	<i>P</i> -value <sup>b</sup>
	AA	AG / GG	AA	AG / GG			
<i>Donor</i>	48 (80.0%)	12 (20.0%)	1076 (89.1%)	131 (10.9%)	<b>0.029</b>	<b>2.05</b> (1.06 – 3.97)	<b>0.032</b>
<i>Recipient</i>	56 (93.3%)	4 (6.7%)	1079 (89.2%)	56 (4.9%)	0.31		0.32

3  
4 Differences in the occurrence of primary non-function (PNF) based on donor and recipient tumor  
5 necrosis factor-alpha genotypes.

6 Abbreviations: 95-CI%, 95% confidence interval; SNP, single nucleotide polymorphism; *TNF*, recipient  
7 tumor necrosis factor-alpha gene.

8 Bold *P-values* indicate *P-values* that are statistically significant (*P*-value < 0.05).

9 <sup>a</sup> *P*-value for the Pearson Chi-square test for differences in genotype frequency.

10 <sup>b</sup> *P*-value for univariate logistic regression analysis for differences in the incidence of primary  
11 non-function.

12

1 **Table 3**  
 2 **Associations of *TNF* polymorphism in the donor with immediate graft loss after kidney**  
 3 **transplantation.**

Variables not in the equation		Variables in the equation		
Variables	P-value	Variables	P-value	Hazard Ratio
Cold ischemia time ( <i>In hours</i> )	0.39	rs3093662-G in the donor (G versus A)	0.032	2.16 (1.07 – 4.37)
		Donor age ( <i>In years</i> )	0.017	1.03 (1.00 – 1.05)
		Donor type ( <i>Deceased versus living</i> )	0.002	9.53 (2.29 – 39.8)
		Recipient sex ( <i>Male versus female</i> )	0.028	0.51 (0.28 – 0.93)
		Recipient blood type ( <i>AB versus other</i> )	0.027	
		Warm ischemia time ( <i>In minutes</i> )	0.006	1.03 (1.01 – 1.05)

4  
 5 Multivariable logistic regression was performed for primary non-function (PNF) with a stepwise forward  
 6 selection. All variables with a *P*-value < 0.05 in the univariate analysis for PNF were included. Data are  
 7 presented as odds ratio with 95%-confidence interval (95%-CI) and *P*-value. In the final model, the *TNF*  
 8 rs3093662 A>G polymorphism in the donor, donor type, recipient sex, recipient blood type, and warm  
 9 ischemia time were included, whereas cold ischemia time was not.  
 10



1 **Table 4**  
 2 **Competitive analysis of the associations of characteristics with late graft loss after kidney**  
 3 **transplantation.**

Variables not in the equation		Variables in the equation		
Variables	P-value	Variables	P-value	Hazard Ratio
Donor blood type ( <i>AB versus other</i> )	0.93	rs3093662-G in the donor ( <i>A versus G</i> )	0.028	1.51 (1.05 – 2.19)
Donor type ( <i>living versus deceased</i> )	0.11	Donor age ( <i>in years</i> )	0.002	1.02 (1.01 – 1.03)
Cold ischemia time ( <i>in hours</i> )	0.11	Recipient age ( <i>in years</i> )	<0.001	0.98 (0.97 – 0.99)
Warm ischemia time ( <i>in minutes</i> )	0.08	Recipient blood type ( <i>AB versus other</i> )	0.001	
Corticosteroids	0.08	Delayed graft function ( <i>yes versus no</i> )	<0.001	4.00 (3.03 – 5.30)
Cyclosporin	0.27			


4  
 5 Multivariable cox regression was performed for 15-year death-censored kidney graft survival with a  
 6 stepwise forward selection. All variables with a *P*-value < 0.05 in the univariate analysis for late graft  
 7 loss were included. Data are presented as hazard ratio with 95% confidence interval (CI) and *P*-value.  
 8 In the final model, the *TNF* rs1800629 G>A polymorphism in the donor, recipient and donor age,  
 9 recipient blood type and delayed graft function (DGF) were included, whereas donor blood type, donor  
 10 type, cold ischemia time, warm ischemia time, and use of cyclosporin and corticosteroids were not.  
 11

1 **Figures**

2

3 **Figure 1**

4 **Examined polymorphisms in the tumor necrosis factor-alpha gene**



5


6 To assess the impact of single nucleotide polymorphisms (SNP) in the tumor necrosis factor-alpha (TNF-  
7  $\alpha$ ) gene (*TNF*) in kidney transplantation, we assessed the association between graft survival outcomes  
8 and the (A) *TNF* SNP rs1800629 G>A and the (B) *TNF* SNP rs3093662 A>G in the donors and recipients.  
9 The *TNF* SNP rs1800629 G>A is located in the promoter region while the *TNF* SNP rs3093662 A>G is  
10 in the first intron of the gene.

11

1 **Figure 2**

2 **Kaplan-Meier curves for 5-year, 10-year, and 15-year death-censored graft survival after kidney**  
 3 **transplantation according to the *TNF* rs3093662 polymorphism in the donor.**

4



5


6 Cumulative (A) 5-year, (B) 10-year, and (C) 15-year death-censored kidney graft survival according to  
 7 the presence of the rs3093662 A>G polymorphism in the tumor necrosis factor-alpha gene (*TNF*) in the  
 8 donor. Furthermore, Kaplan-Meier curves for 15-year death-censored graft survival after kidney  
 9 transplantation were reanalyzed after excluding donor and recipient kidney transplant pairs with primary  
 10 non-function (PNF) (D). The incidence of graft loss among the groups was compared using the Log-  
 11 rank test.

12

1 **Figure 3**

2 **Kaplan-Meier curves for 15-year death-censored graft survival after kidney transplantation**  
 3 **according to the *TNF* rs3093662 polymorphism in living and deceased kidney donors.**

4



5


6 A subgroup analysis for donor type was performed to look at the cumulative 15-year death-censored  
 7 kidney graft survival according to the presence of the rs3093662 A>G polymorphism in the tumor  
 8 necrosis factor-alpha gene (*TNF*) in (A) living kidney donors and (B) deceased kidney donors. The Log-  
 9 rank test was used to compare the graft loss incidence between the different groups.

1 **Supplementary Figures**

2

3 **Figure S1**

4 **Kaplan-Meier curves for 15-year death-censored graft survival after kidney transplantation**  
5 **according to the presence of TNF variant in the donor and recipient.**



6

7 Cumulative 15-year death-censored kidney graft survival according to the presence of (A) the  
8 rs3093662 A>G polymorphism in the tumor necrosis factor- $\alpha$  gene (*TNF*) in the recipient, and the  
9 presence of the rs1800472 G>A polymorphism in *TNF* in the (B) donor and (C) recipient. The Log-rank  
10 test was used to compare the graft loss incidence between the different groups.